We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Acadia Pharmaceuticals Inc | NASDAQ:ACAD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.34 | 2.03% | 17.05 | 16.40 | 17.63 | 17.57 | 16.84 | 16.84 | 1,627,841 | 01:00:00 |
FORM 3
| Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
| |
1. Name and Address of Reporting Person * Teehan Brendan |
2. Date of Event Requiring Statement (MM/DD/YYYY)
| 3. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ACAD] |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) EVP, COO, Head of Commercial / | ||
5. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned | |||
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 807 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Employee Stock Option (Right to Buy) | (1) | 7/15/2028 | Common Stock | 52500 | $16.87 | D | |
Employee Stock Option (Right to Buy) | (2) | 4/28/2029 | Common Stock | 10993 | $25.12 | D | |
Employee Stock Option (Right to Buy) | (3) | 1/5/2030 | Common Stock | 9336 | $42.81 | D | |
Employee Stock Option (Right to Buy) | (4) | 2/22/2031 | Common Stock | 8152 | $49.74 | D | |
Restricted Stock Units | (5) | (5) | Common Stock | 3134 | (6) | D | |
Restricted Stock Units | (7) | (7) | Common Stock | 3859 | (6) | D | |
Restricted Stock Units | (8) | (8) | Common Stock | 4427 | (6) | D |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Teehan Brendan C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO, CA 92130 | EVP, COO, Head of Commercial |
Signatures | ||
/s/ Austin D. Kim, Attorney-in-Fact | 11/5/2021 | |
**Signature of Reporting Person | Date |
1 Year Acadia Pharmaceuticals Chart |
1 Month Acadia Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions